Skip to content
10-K

Annual Report

Quoin Pharmaceuticals, Ltd. QNRX

0001104659-26-035251

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow FY 2025 · Dec 31, 2025 −$13.54M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$7.86M
Short Term Investments FY 2025 · Dec 31, 2025 $14.93M
Short Term Investments FY 2025 · Dec 31, 2024 $10.43M
Cash And Equivalents FY 2025 · Dec 31, 2025 $3.82M
Cash And Equivalents FY 2025 · Dec 31, 2024 $3.62M
Stockholders Equity FY 2025 · Dec 31, 2025 $13.12M
Stockholders Equity FY 2025 · Dec 31, 2024 $9.2M
Stockholders Equity FY 2025 · Dec 31, 2023 $5.66M
Current Liabilities FY 2025 · Dec 31, 2025 $5.55M
Current Liabilities FY 2025 · Dec 31, 2024 $4.18M
Total Liabilities FY 2025 · Dec 31, 2025 $7.27M
Total Liabilities FY 2025 · Dec 31, 2024 $6.5M
Current Assets FY 2025 · Dec 31, 2025 $20.01M
Current Assets FY 2025 · Dec 31, 2024 $14.93M
Total Assets FY 2025 · Dec 31, 2025 $20.39M
Total Assets FY 2025 · Dec 31, 2024 $15.71M
Sga Expense FY 2025 · Dec 31, 2025 $6.49M
Sga Expense FY 2025 · Dec 31, 2024 $5.93M
Rd Expense FY 2025 · Dec 31, 2025 $9.8M
Rd Expense FY 2025 · Dec 31, 2024 $3.6M
Net Income FY 2025 · Dec 31, 2025 −$15.8M
Net Income FY 2025 · Dec 31, 2024 −$8.96M